Meningococcal disease is a serious bacterial infection that causes meningitis (inflammation of the membranes surrounding the brain and spinal cord) and sepsis (blood infection). If not treated quickly with antibiotics, meningococcal disease can lead to death or permanent disabilities such as hearing loss, neurological damage, limb amputations, or kidney damage. While the disease is not very common, it develops rapidly and has a high fatality rate of around 10-15%. The infection is usually spread through respiratory and throat secretions from carriers of the bacteria. Close and prolonged contact or living in close quarters with an infected individual facilitates transmission.

Types of Meningococcal Vaccines

There are two main types of vaccines available that offer protection against meningococcal disease - polysaccharide vaccines and conjugate vaccines. Polysaccharide vaccines (Menomune, Mencevax) contain polysaccharides (sugars) from the coats of four meningococcal bacteria strains (A, C, Y, W-135). However, these vaccines produce a relatively weak immune response and limited duration of protection, especially in young children. Conjugate vaccines were developed to boost immunity by conjugating (chemically binding) the polysaccharides to carrier proteins like Diphtheria toxoid.

Currently available conjugate vaccines are Menactra, Menveo and Bexsero. Menactra and Menveo protect against serogroups A, C, W and Y. Bexsero offers broader protection against serogroup B, which causes the majority of meningococcal disease in many countries including the United States. Conjugate vaccines produce a stronger, longer-lasting immunity compared to polysaccharide vaccines and are recommended for all age groups including children as young as 9 months.

Who Should Get Vaccinated?

The Centers for Disease Control and Prevention (CDC) recommends routine vaccination for the following high-risk groups in the United States:

- Children at 11-12 years old as a routine adolescent immunization

- College freshmen living in dormitories

- Laboratory personnel routinely exposed to meningococcal isolates

- United States military recruits

- Anyone with asplenia or sickle cell disease

- Anyone with HIV infection or undergoing treatment for cancer

- Travelers to or residents of countries where meningococcal disease is hyperendemic or epidemic like parts of Africa

The CDC also recommends vaccination for people experiencing a meningococcal disease outbreak in their community or who may have been exposed during an outbreak. People should speak to their healthcare provider about getting vaccinated to protect themselves and to help prevent the spread during an outbreak.

Importance of Vaccination in Adolescents

While meningococcal disease can occur at any age, rates are highest in infants less than 1 year old as well as adolescents and young adults 16-21 years old. Adolescents and young adults account for nearly 30% of all meningococcal disease cases, likely due to changes in social behaviors that promote close contact when bacteria can spread. Immunizing adolescents at 11-12 years old as a routine part of their Tdap/TD booster provides protection at the age when risk is highest. Vaccination also helps establish "herd immunity" in the community to indirectly protect unvaccinated individuals. For these reasons, the adolescent meningococcal vaccine is crucial in preventing infections that can be debilitating or even fatal during this high-risk life stage.

Vaccine Safety and Efficacy

Studies show that meningococcal conjugate vaccines are very safe and effective at preventing invasive disease from the targeted serogroups. Clinical trials for Menactra and Menveo demonstrated 85-100% efficacy within 3-5 years of vaccination in participants 2 months through 25 years old. In clinical trials, Bexsero showed efficacy ranging between 53-84% in preventing MenB disease. A robust immune response helps confer prolonged protection against invasive meningococcal disease. Reported side effects from the vaccines are typically mild, including soreness at the injection site and low-grade fever. The conjugate vaccines have an excellent safety profile and have not been shown to cause any serious or long-term health issues. Healthcare providers closely monitor the Advisory Committee on Immunization Practices' vaccine recommendations to ensure people receive the appropriate serogroup vaccines based on their individual circumstances and the local epidemiology.

Continued Surveillance and Development Needed

While vaccination programs have reduced meningococcal disease rates in many parts of the world, ongoing surveillance and new vaccine development are important to address changing epidemiology patterns and emerging threats from new strains. Medical databases closely track disease incidence, outbreaks, and serogroup distribution to inform vaccine policies. Research continues into multicomponent protein-based MenB vaccines that could provide broader protection against strains not covered by existing serogroup vaccines. International coordination through organizations like the World Health Organization help deploy vaccines equitably to curb epidemics occurring mainly in developing countries with limited healthcare infrastructure. With sustained immunization efforts and scientific advancements, experts hope to control meningococcal disease burden globally through strategic, evidence-based public health interventions.

Get More Insights Here

https://coolbio.org/system-on-a-chip-soc-the-future-of-electronics/

https://www.pressreleasebulletin.com/protecting-against-a-potentially-deadly-disease/